A Phase IIb, 96 Week, Randomized, Open-Label, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Different Doses and Regimens of GW873140 [aplaviroc] in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy Naive Subjects.
Latest Information Update: 04 Jul 2023
Price :
$35 *
At a glance
- Drugs Aplaviroc (Primary) ; Lamivudine/zidovudine; Lopinavir/ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms EPIC
- Sponsors GlaxoSmithKline; GSK
- 02 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 01 Feb 2009 Results were published in HIV Medicine in 2009.